Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection

Abstract

Patients with colonic adenocarcinoma (COAD) are at relatively high risk of SARS-CoV-2 infection. However, there is a lack of medical strategies to treat COVID-19/COAD comorbidity. Puerarin, a natural product, is a known antiviral, antitumor, and immunomodulatory effect. Therefore, we hypothesised that puerarin could be used to treat COVID-19/COAD patients. Based on network pharmacology and bioinformatics analysis, the potential targets and pharmacological mechanisms of puerarin in COVID-19/COAD were identified. By intersecting therapeutic target genes for puerarin, COVID-19-related genes and COAD-related genes, 42 target genes of puerarin that could potentially treat COVID-19/COAD comorbidity were obtained. By using the 42 potential target genes to construct the protein-protein interaction (PPI) network, we obtained five core target genes, namely RELA, BCL2, JUN, FOS, and MAPK1. The results of bioinformatics analysis revealed that puerarin could be able to treat COVID-19/COAD comorbidity through apoptosis, antiviral, antioxidant, NF-κB signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and HIF-1 signaling pathway etc. This study found that puerarin has the potential to treat COVID-19/COAD patients and that the therapeutic target genes obtained in the study may provide clues for the treatment of COVID19/COAD comorbidity.

Evaluation of Antibacterial and Antioxidant Activities of Stingless Bee (Tetragonula Laeviceps) Hive from Purwodadi Botanical Garden and LC/MS Profiles of Dichloromethane Fraction

“…ncbi.nlm.nih.gov/). This metabolite has a potential therapeutic for SARS-CoV-2, Hantavirus co-infection, and colon adenocarcinoma [34,35]. In contrast, irisflorentin is a member of 4 -methoxyisoflavones.…”

Bioinformatics analysis of potential pathogenesis and risk genes of immunoinflammation-promoted renal injury in severe COVID-19

“…The GSE157103 dataset was used as an independent validation set, for sample selection, see sections 2.8 and 2.9. All patients with COVID-19 in the dataset were confirmed positive by PCR, and the classification criteria for mild, moderate, and severe COVID-19 among different datasets were classified according to international guidelines for the severity of COVID-19 (18)(19)(20)(21)(22)(23)(24). GSE98622 ( 25) is a dataset of renal ischemia-reperfusion injury (IRI) which contains 18 normal mouse kidneys and 10 consecutive time points of IRI kidney injury data, with 3 samples for each time point.…”

Investigating gene signatures associated with immunity in colon adenocarcinoma to predict the immunotherapy effectiveness using NFM and WGCNA algorithms

“…Colon adenocarcinoma (COAD), one of the most common malignancies, is among the top five in terms of morbidity and death from tumor-related illnesses [1][2][3][4]. Predictions indicate that in 2022, colorectal cancer (CRC) diagnoses will number 600,000 in China and 160,000 in the US, with 300,000 and 55,000 cases of CRC-related deaths in each country, respectively [5].…”